PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
Key Highlights
- ➤Pooled analysis covered 2,185 patients across one Phase 2 and two Phase 3 trials
- ➤Heavy bacterial growth was 16% with D-PLEX₁₀₀ versus 27% with standard of care
- ➤Breakthrough SSIs occurred later with D-PLEX₁₀₀: median 10.0 versus 6.5 days
- ➤Multidrug-resistant organism proportions were similar between treatment groups
- ➤SHIELD II showed 60% relative SSI-risk reduction; FDA NDA remains under review
Expert Statements
Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid
“Preventing surgical-site infections remains our primary objective. Part of infection prevention is understanding the microbiology of infections that occur despite prophylaxis. This matters even more as antimicrobial resistance is a first-order global health threat(1). This exploratory pooled analysis showed that compared with standard of care alone, treatment with D-PLEX₁₀₀ was associated with lower burden of bacterial growth, without evidence of increased antimicrobial resistance. Together with the later recorded onset of breakthrough SSIs, these findings suggest that D-PLEX₁₀₀ do not only demonstrate a relative risk reduction by 60% in the postoperative infection as seen in the SHIELD II trial, but also favourably impact the microbiologic characteristics and severity of infections that emerge despite treatment”
PETACH TIKVA, Israel, Oct. 21, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will present an oral presentation at IDWeek 2026 on Thursday, October 22, 2026, in Washington, D.C. The presentation will focus on an exploratory pooled analysis of microbiology from SHIELD I, SHIELD II, and D-PLEX₁₀₀ phase 2 trial involving 2,185 patients, demonstrating a lower bacterial burden in breakthrough surgical-site infections (“SSIs”) and later occurrence of breakthrough SSIs in the D-PLEX₁₀₀ treatment arm compared to standard of care (“SoC”), with similar proportions of multidrug-resistant organisms between treatment groups.
The presentation, titled "D-PLEX₁₀₀ Lowers the Microbial Burden Without Selecting for Multidrug-Resistant Bacteria: Pooled Microbiology from Three Randomized Trials (N=2,185)," will be delivered by George M. Viola, M.D., M.P.H., Department of Infectious Diseases, Infection Control, and Employee Health, Division of Internal Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas. Co-authors are Nurit Tweezer-Zaks, M.D., M.B.A., and Meidan Dvir, Ph.D.
Get started
Create a free account to read the full story.